Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cindilimab + olaparib
- Development stage
- Preclinical
- Lead developer
- Innovent Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Cindilimab + olaparib is a combination therapy consisting of cindilimab, a monoclonal antibody targeting the programmed cell death protein 1 (PD-1), and olaparib, a small molecule inhibitor of poly(ADP-ribose) polymerase (PARP). Cindilimab acts as an immune checkpoint inhibitor, enhancing T-cell mediated anti-tumor responses by blocking PD-1. Olaparib inhibits PARP enzymes involved in DNA repair, leading to synthetic lethality in tumor cells with homologous recombination deficiencies such as BRCA mutations. This combination is being explored for synergistic antitumor activity in various advanced malignancies.
- Other names
- cindilimab + olaparib
02
Targets
PARP1 (Poly (adp-ribose) polymerase 1)Pol II (RNA polymerase II elongation factors)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on cindilimab + olaparib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cindilimab + olaparib.